Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00830570 · ClinicalTrials.gov registry record

The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings

A clinical trial of Venous Thromboembolism and Vascular Diseases, sponsored by Medco Health Solutions.

Completed
Registry status
1,635
Enrollment target
1
Study location

NCT00830570 is a study of Venous Thromboembolism and Vascular Diseases that has completed, run by Medco Health Solutions. The registered enrollment target is 1,635 participants, below the 6,261-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00830570, a study of Venous Thromboembolism and Vascular Diseases, has completed, sponsored by Medco Health Solutions.

COMPLETED
Registry status
1,635 participants
Enrollment target
1
Study location

Study Summary

The purpose of this quasi-experiment study, which could also be classified as a prospective observational intervention study, is to assess the impact of cytochrome P450 2C9 (CYP 2C9) and vitamin K epoxide reductase complex, subunit 1 (VKORC1) testing within a primary patient care setting.

Interventions

  • OTHER CYP 2C9 and VKORC1 Testing for Warfarin

Study Locations (1)

New Jersey

  • Medco Health Solutions, Inc. - Franklin Lakes

Trial Details

FieldValue
Enrollment Target 1,635 participants
Start Date 2007-07
Est. Completion 2010-01

Sponsor

Medco Health Solutions

6 total trials

What the Registry Record Tells You About NCT00830570

The ClinicalTrials.gov registry entry for NCT00830570 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,635 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,261-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (74% lower). The listed sponsor is Medco Health Solutions, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Venous Thromboembolism appearing as the primary indexed condition, and to 1 intervention - of which CYP 2C9 and VKORC1 Testing for Warfarin is the first listed.

NCT00830570 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT00830570 about?

NCT00830570 is a clinical study titled "The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings". The purpose of this quasi-experiment study, which could also be classified as a prospective observational intervention study, is to assess the impact of cytochrome P450 2C9 (CYP 2C9) and vitamin K epoxide reductase complex, subunit 1 (VKORC1) testing within a primary patient care setting.

What is the current status of trial NCT00830570?

This trial is currently completed. The enrollment target is 1,635 participants. The study started on 2007-07. Estimated completion is 2010-01.

What conditions does trial NCT00830570 study?

This clinical trial studies the following conditions: Venous Thromboembolism, Vascular Diseases, Thrombosis, Thromboembolism, Embolism and Thrombosis.

What interventions are being tested in trial NCT00830570?

The interventions under investigation include: CYP 2C9 and VKORC1 Testing for Warfarin (OTHER).

Who is sponsoring clinical trial NCT00830570?

This trial is sponsored by Medco Health Solutions, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00830570 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Venous Thromboembolism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.